Journal of Cancer Therapy
Vol.06 No.12(2015), Article ID:61519,10 pages
10.4236/jct.2015.612118
Response of Subcutaneous Xenografts of Endometrial Cancer in Nude Mice to Inhibitors of Phosphatidylinositol 3-Kinase/Akt and Mitogen-Activated Protein Kinase (MAPK) Pathways: An Effective Therapeutic Strategy for Endometrial Cancer
Ruixia Guo*, Xinyan Wang, Ruifang Zhang, Huirong Shi, Yuhuan Qiao, Wenjing Yun, Xin Ge, Yan Lin, Jia Lei
Department of Obstetrics and Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
Copyright © 2015 by authors and Scientific Research Publishing Inc.
This work is licensed under the Creative Commons Attribution International License (CC BY).
Received 19 October 2015; accepted 24 November 2015; published 27 November 2015
ABSTRACT
Objective: This study was designed to explore whether inhibition of the extracellular-regulated kinase (ERK) and phosphatidylinositol-3-kinase (PI3K) signaling pathways can inhibit the growth of xenografts of endometrial cancer cell lines with different estrogen receptors (ER) profiles in vivo and to provide preliminary laboratory basis for the probability of endometrial adenocarcinoma treatment with blockage of the two pathways, especially to endometrial cancer with low ER status. Methods: Human endometrial cancer Ishikawa bearing ER and HEC
Keywords:
Extracellular-Regulated Kinase (ERK), Proto-Oncogene Proteins, Akt, ERK Pathway Inhibitor, PD98059, Phosphatidylinositol-3-Kinase Pathway Inhibitor, LY294002, Endometrial Cancer Cell, Estrogen Receptor
1. Introduction
Endometrial carcinoma is one of the most common gynecological carcinomas. Two types of endometrial cancers have been described based on clinical and histopathology features. Type I endometrial carcinomas are usually found in patients with a high estrogen level that is unopposed by progestin. These well-differentiated tumors have good response to endocrinal therapy and a good prognosis. On the other hand, type II is generally associated with the normal estrogen state and usually shows poor response to endocrinal therapy. These tumors are usually poorly differentiated, highly malignant and present bad prognosis. Therefore, it is necessary to find a new strategy for the treatment of endometrial cancers, especially for type II.
Prior studies of endometrial carcinoma cell lines have shown that 17β-estradiol can activate the PI3K/Akt and MAPK/ERK signaling pathways [1] - [4] . It is widely accepted that MAPK/ERK and PI3K/Akt signaling cascades play critical roles in the transmission of signals that regulate gene expression, prevent apoptosis, and influence tumor progression and the effectiveness of anti-tumor therapy [5] -[8] . Mutation or aberrant expression of the components of these pathways has been observed in a variety of human cancers such as ovarian and endometrial cancers. For example, the levels of P-Akt and P-ERK found in endometrial adenocarcinoma and atypical endometrial hyperplasia were significantly higher than that in the proliferative phase endometrium [9] [10] .
As a downstream target protein of PI3K, Akt is the core of the PI3K/Akt signaling pathway. Akt is also known as protein kinase B (PKB) and consists of three distinct domains: an aminoterminal pleckstrin homology (PH) domain containing a region for binding inositol phospholipids, a kinase domain, and a carboxyl terminal regulatory domain [8] . Akt is fully activated with phosphorylation Thr308 and Ser473, activated Akt is also called phosphorylated Akt (P-Akt). P-Akt induces the phosphorylation of its downstream targets, promotes tumor cell growth, hinders apoptosis, and contributes to tumor angiogenesis [11] [12] .
The mitogen-activated protein kinase pathway (MAPK/MEK/ERK1/2) is another important signaling pathway which converts extracellular stimulation to intracellular signals that control gene expression, cell proliferation, differentiation, and survival. It plays an important role in the process of cell malignant transformation. The MAPK signaling pathway activates ERK1/2 through multiple kinase cascades. The phosphorylation ERK1/2 (P-ERK1/2) is activated and then transfers signals from cell surface receptors to the nucleus: p-ERK1/2 transfers into nucleus to regulate various transcription factors such as e-Mye, sTArs, Jun, Fos, ATFZ and Max. These transcription factors further regulate their own target genes, causing specific changes in protein expression or activity, and ultimately regulate the cell metabolism and function to produce specific biological effects [13] . Blocking MAPK/ERK or PI3K/Akt signaling pathways could suppress cell proliferation of endometrial cancers in vitro [5] [14] . It has been recognized that the activation of MAPK/ERK or PI3K/Akt signaling pathways is closely related to the occurrence and development of endometrial cancers nowadays. As a result, blocking these pathways might be supposed as a new molecular target therapy in endometrial carcinomas.
PD98059 and LY294002 can specifically block the MAPK/ERK1/2 or PI3K/Akt signaling pathways by inhibiting the activation of ERK1/2 or Akt, respectively. Here, we studied the effects of PD98059 and LY294002 on xenograft tumors of Ishikawa and HEC
2. Materials and Methods
2.1. Cell Lines and Culturing
The human endometrial carcinoma cell lines Ishikawa and HEC
Female BALB/c nude mice were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. and raised in the Experimental Animal Center of Henan Province, Clean Animal Room (SPF). A concentration of 1 × 108 cells in 1ml phosphate-buffered saline (PBS) was chosen as the suitable number of cells to be injected based on a pilot study. Mice at the age of 4 - 6 weeks (n = 48) were injected subcutaneously with human Ishikawa or HEC
2.2. Pathological Analysis
Parts of the xenograft tumors were paraffin embedded, sectioned and H/E-stained for pathological examination.
2.3. Apoptosis Analysis
The terminal deoxy-UTP nick-end labeling (TUNEL) assays were carried out using an in situ apoptosis detection kit (KGI Biological Development Co., Ltd. Nanjing). Experiments were carried out following the manufacturer’s instructions. In brief, three tissue biopsies were obtained from each individual paraffin-embedded tissue sample. The tissue biopsies were permeabilized with protein K at 37˚C for 20 min and washed twice with PBS. Terminal deoxynucleotidyl transferase solution was added to the tissue biopsies which were then incubated for 1 h in a 37˚C humidified incubator. They were then washed three times with PBS, and incubated in Streptavidin- HRP solution for 30 min at 37˚C. After washing thrice in PBS, the tissue biopsies were stained with DAB and Hematoxylin, and examined under an inverted microscope. The percentage of apoptotic nuclei was calculated as a percentage of the total counted nuclei from scoring at least 100 cells. Each count was repeated three times to ensure accuracy.
2.4. Western Blot Analysis
Tumor tissues were homogenized in lysis buffer with a glass tissue homogenizer according to standard protocols. The lysates were centrifuged at 15,000 g for 10 minutes at 4˚C and the supernatants were collected. The protein concentration of the supernatants was then measured. The extracted proteins were denatured at 100˚C before being subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto nitrocellulose membranes. The membranes (PVDF) were incubated in a blocking solution containing 5% skim milk in Tris-buffered saline supplemented with 0.1% Tween 20 (TBST) for 1 hour at room temperature. The resulting membranes were incubated overnight at 4˚C with the appropriate primary antibodies diluted in the blocking solution. The blots were then incubated with horseradish peroxidase-conjugated secondary antibodies (1:1000 dilutions in TBST) at room temperature for 1 hour. The proteins were then detected with the enhanced chemiluminecence system (ECL, Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd.). The membrane was subsequently exposed to X-Kodak films for about 45s and then processed. The above procedures were repeated for Western blot analysis. All primary antibodies (Rabbit polyclonal antibodies against human phosphorylated Akt (Ser473) and Mouse anti-human ERK1/2 monoclonal antibody (sc7383), Santa Cruz Biotechnology) were used at 1:500 dilution and all secondary antibodies (Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd.) were used at 1:1000 dilution. The activation of Akt and ERK1/2 was defined as the ratio of the p-Akt and p-ERK1/2 to β-actin and quantitatively evaluated after measuring the optical density of the protein bands.
2.5. Statistics
Data analysis was performed using the SPSS (17.0) software package. All data are expressed as mean ± standard deviation (X ± SD). Unpaired t test was used for analyzing pairs of data whereas comparison among various groups was performed by analysis of variance (ANOVA). P < 0.05 was considered statistically significant.
3. Results
To determine whether the effects of PD98059 and LY294002 on xenograft tumors of endometrial carcinoma cells were correlated with estrogen receptor (ER) status, we established xenograft tumor models with Ishikawa and HEC
3.1. Effects of PD98059 and LY294002 on Xenograft Tumors of Ishikawa Cells
Macroscopically, the mice began to show a tumor of palpable size about 8 days after being injected with Ishikawa cells,, but the growth rates of those tumors were different in the four groups (Figure 2(A). F = 23.056, P = 0.000). Relative to the controls, LY294002 induced significant suppression in the growth of Ishikawa cell xenograft tumors. The mean volume of tumors treated with LY294002 (1874.56 ±
Figure 1. Establishment of xenograft tumors in nude mice. (A) representative xenograft models of the Ishikawa cell line. (B) representative xenograft models of the HEC-1A cell line. (C), (D) representative xenograft tumors in mice in different treatment groups.
(A) (B) (C)
Figure 2. Effect of PD98059, LY294002 and their combination on the growth of human endometrial carcinoma xenografts. Ishikawa (A) and HEC-1A (B) cells were grown as xenografts in nude mice. After tumor establishment (14 days after cells were injected, tumor volume reached about 80 mm3), mice were treated with PD98059, LY294002, PD98059 + LY294002 or saline by intraperitoneal injection for 3 weeks. Tumors were measured twice a week using calipers. Both PD98059 and LY294002 significantly delayed tumor growth in both Ishikawa (A) and HEC-1A (B) cell xenograft models when compared with the control, and their inhibitory effect was enhanced when they were used simultaneously. (C) Bar diagram representing mean ± SD of tumor inhibition ratios, *P < 0.01 compared between groups treated with PD98059 or LY294002 only.
(A) (B)
(C) (D)
(E) (F)
(G) (H)
Figure 3. H/E staining (×40) of xenograft tumors. Representative H/E-stained sections of Ishikawa (A)-(D) and HEC-1A cell (E)-(H) xenografts in different groups. Compared with the controls, the number of tumor cells decreased and the number of nuclei decreased by varying degrees in groups treated with PD98059, LY294002 or a combination of both.
tionally, in xenograft tumors arising from these cell lines, there was no significant difference between the efficiency
Figure 4. The effects of PD98059 and LY294002 on the rate of apoptosis. Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling assay was conducted on the control, LY294002, PD98059 and PD98059 + LY294002 groups. Apoptosis was measured in paraffin-embedded xenograft tumors of Ishikawa and HEC-1A cells (×40). The apoptosis rate in the xenografts of different groups (I), presented as mean ± SD, *P < 0.01, #P < 0.01 compared with the control group of their corresponding cell line.
of LY294002 and PD
3.2. Effects of PD98059 and LY294002 on Xenograft Tumors of HEC
We found that LY294002 effectively inhibited the growth of xenograft tumors (mean volume = 1791.5 ±
3.3. PD98059 and LY294002 Reduced the Activation of PI3K and MAPK Pathways in Ishikawa and HEC
To study the constitutive activation of PI3K/Akt and MAPK/ERK1/
We tested the effects of PI3K inhibitors LY294002, the MAPK inhibitors PD98059 and their combinations on the activation of Akt and ERK1/2 by western blot analysis in vivo. It revealed that LY294002 induced decreased levels of p-Akt protein expression in xenografts of both Ishikawa (F = 462.084, P < 0.05) and HEC
4. Discussion
In this study, we found that intraperitoneal injection of the specific PI3K inhibitor LY294002 or MAPK inhibitor PD98059 effectively suppresses endometrial cancer xenograft tumors growth by inducing apoptosis in vivo. Our observations are consistent with previous studies on endometrial cancer cells in vitro [5] [14] . We also found that the inhibitory effect on these xenografts were more significant when the PI3K/Akt and MAPK/ERK1/2
pathways were inhibited simultaneously.
Akt and ERK1/2 have previously been shown to be constitutively active in premalignant and malignant human endometrial cancers [9] [10] . They are known to stimulate cell proliferation, inhibit apoptosis and thus prolong cell survival endometrial cancer in vitro upon activation by stimuli such as estradiol (E2) and SDF-1α
(A) (B)
Figure 5. The p-Akt and p-ERK1/2 levels in control xenografts of Ishikawa and HEC-1A cell was analyzed by western blot. Xenografts of Ishikawa and HEC-1A cell lines have different p-Akt, p-ERK1/2 levels (A-B).*P < 0.01.
(A) (B)
(C) (D)
Figure 6. The p-Akt and p-ERK1/2 levels in xenografts of different groups were detected by western blot. (A): Levels of p-Akt and p-ERK1/2 in xenografts of HEC-1A cell lines. (B): Levels of p-Akt and p-ERK1/2 in xenografts of Ishikawa cell lines. (C), (D): bar diagram of the ratios of p-Akt:β-actin and p-ERK1/2:β-actin in the two endometrial cancer cell groups. The results represent mean ± SD of three independent experiments each performed in triplicate (*P < 0.01; #P < 0.01 compared with the controls).
[1] - [4] [15] . Thus, activation of the PI3K/Akt and MAPK/ERK1/2 pathways likely play important roles in the occurrence and development of endometrial cancer. Additionally, these signaling pathways may be important potential targets for chemoprevention and treatment of endometrial cancer.
Ishikawa and HEC
In order to further investigate whether the activation of PI3K/Akt and MAPK/MEK/ERK1/2 signaling pathways and the inhibitory effects of their inhibitors are related to ER expression profiles, we selected both the Ishikawa and HEC
Our results show that LY294002 and PD98059 showed remarkable anti-tumor effects on both Ishikawa and HEC
Furthermore, we evaluated levels of p-Akt and p-ERK1/
Several studies have reported evidence suggesting extensive cross-talk between the PI3K/Akt and MAPK/ ERK1/2 signaling pathways. Some studies suggest that the activity of PI3K plays an important role in the induction of the Ras/MAPK pathway. In addition,inhibitor of the PI3K has been reported to attenuate the activity of MAPK, and this effect could occur at different levels of the Ras/MAPKERK pathway. For example, wortmannin has been shown to block the ERK1/2 activation induced by CD3 antibody in T cells and MAPK activation in the skeletal muscle of rabbits [22] . Lee et al. found that the PI3K/Akt signaling pathway has a regulatory role on the activation of ERK1/2 [23] . Our observation that concurrent inhibition of the PI3K/Akt and MAPK/ERK1/2 pathways had synergistic effects and showed enhanced anti-proliferative effects in vivo by increasing apoptosis, also suggests that complex interactions may exist between the two pathways. However, the nature and mechanism of the interaction is unclear. Further research on the interactions between these pathways may lead us to more effective treatments for cancer.
5. Conclusion
In summary, we found that LY294002 and PD98059 both inhibited the growth of xenografts of cells with different ER profiles by blocking the PI3K/Akt and MAPK/ERK1/2 signaling pathways, respectively, in vivo. Our findings suggest that targeting these pathways may be an effective alternative for treatment of endometrial cancer, especially for ER-negative endometrial cancer.
Acknowledgements
This study was supported by grants from the Henan Science and Technology Innovation Talents Foundation (2010HASTTTDD5).
Cite this paper
RuixiaGuo,XinyanWang,RuifangZhang,HuirongShi,YuhuanQiao,WenjingYun,XinGe,YanLin,JiaLei, (2015) Response of Subcutaneous Xenografts of Endometrial Cancer in Nude Mice to Inhibitors of Phosphatidylinositol 3-Kinase/Akt and Mitogen-Activated Protein Kinase (MAPK) Pathways: An Effective Therapeutic Strategy for Endometrial Cancer. Journal of Cancer Therapy,06,1083-1092. doi: 10.4236/jct.2015.612118
References
- 1. Guo, R.X., Wei, L.H., Wang, J.L., et al. (2004) [Activation of Phosphatidylinositol 3-Kinase-Protein Kinase B(PI3K-PKB) Induced by 17β-Estradiol in Endometrial Carcinoma Cell (Ishikawa)]. Chinese Journal of Obstetrics and Gynecology, 39, 469-473. (In Chinese)
- 2. Guo, R.X., Wei, L.H. and Wang, J.L. (2005) [Activation of Phosphatidylinositol 3-Kinase-Proteinkinase B(PI-3K-PKB) Induced by 17β-Estradiol in Endometrial Carcinoma Cell HEC-1A)]. Progress in Obstetrics and Gynecology, 14, 270-273. (In Chinese)
- 3. Guo, R.X., Wei, L.H., Tu, Z., et al. (2006) 17 β-Estradiol Activates PI3K/Akt Signaling Pathway by Estrogen Receptor (ER)-Dependent and ER-Independent Mechanisms in Endometrial Cancer Cells. The Journal of Steroid Biochemistry and Molecular Biology, 99, 9-18.
http://dx.doi.org/10.1016/j.jsbmb.2005.11.013 - 4. Huang, S.S., Guo, R.X. and Qiao, Y.H. (2009) [Effect of 17β-Estradiol on Proliferation and Expressions of P21ras and p-Erk in Endometrial Carcinoma Cells]. Progress in Obstetrics and Gynecology, 18, 17-21. (In Chinese)
- 5. Guo, R.X., Wei, L.H., Qiao, Y.H., et al. (2006) Blockage of PI3K/PKB/P27kip1 Signaling Pathway Can Antagonize 17β-Estradiol Induced Ishikawa Proliferation and Cell Cycle Progression. Chinese Medical Journal, 119, 242-245
- 6. Kohno, M. and Pouyssegur, J. (2006) Targeting the ERK Signaling Pathway in Cancer Therapy. Annals of Medicine, 38, 200-211.
http://dx.doi.org/10.1080/07853890600551037 - 7. Hilger, R.A., Scheulen, M.E. and Strumberg, D. (2002) The Ras-Raf-MEK-ERK Pathway in the Treatment of Cancer. Onkologie, 25, 511-518.
http://dx.doi.org/10.1159/000068621 - 8. Krasilnikov, M.A. (2000) Phosphatidylinositol-3 Kinase Dependent Pathways: The Role in Control of Cell Growth, Survival, and Malignant Transformation. Biochemistry, 65, 59-67.
- 9. Guo, R.X., Guo, H.M., Yuan, Z.F., et al. (2009) [The Expressions of G Protein-Coupled Receptor 30 and Phosphorylated AKT in Endometrial Adenocarcinoma]. Progress in Obstetrics and Gynecology, 18, 881-884. (In Chinese)
- 10. Qiao, Y.H., Niu, Q., Guo, R.X., et al. (2009) [The Clinicopathologic Significance of P21Ras and P-ERK Expression in Endometrial Carcinoma]. Chinese Journal of Clinical Obstetrics and Gynecology, 10, 277-280. (In Chinese)
- 11. Shaw, R.J. and Cantley, L.C. (2006) Ras, PI(3)K and mTOR Signalling Controls Tumour Cell Growth. Nature, 441, 424-430.
http://dx.doi.org/10.1038/nature04869 - 12. Vivanco, I. and Sawyers, C.L. (2002) The Phosphatidylinositol 3-Kinase AKT Pathway in Human Cancer. Nature Reviews Cancer, 2, 489-501.
http://dx.doi.org/10.1038/nrc839 - 13. Sehulze, A., Nieke, B., Wame, P.H., et al. (2004) The Transeriptional Response to Raf Activation Is Almost Completely Dependent on Mitogen-Activated Protein Kinase Activity And Shows a Major Autocrine Component. Molecular Biology of the Cell, 15, 3450-3463.
http://dx.doi.org/10.1091/mbc.E03-11-0807 - 14. Guo, R.X., Qiao, Y.H. and Wei, L.H. 2007 [Effect of Phosphatidylinositol-3 Kinase Inhibitor on 17β-Estradiol-Induced Proliferation and Apoptosis in Ishikawa and HEC-1A Cells]. Journal of Zhengzhou University (Medical Sciences), 42, 322-326. (In Chinese)
- 15. Zhao, D., Li, X.-P., Wei, L.-H., et al. (2006) Stromal Cell-Derived Factor 1α Stimulates Human Endometrial Carcinoma Cell Growth through the Activation of Both Extracellular Signal-Regulated Kinase 1/2 and Akt. Gynecologic Oncology, 103, 932-937.
http://dx.doi.org/10.1016/j.ygyno.2006.05.045 - 16. Guo, R.X., Wang, J.L., Zhao, D., et al. (2005) [Expressions of Estrogen Receptor α and β in Endometrial Carcinoma Cell Lines, Ishikawa and HEC-1A]. Chinese Journal of Clinical Obstetrics and Gynecology, 6, 272-274. (In Chinese)
- 17. Yaginuma, Y., Yamashita, T., Ishiva, T., et al. (2000) Abnormal Structure and Expression of PTEN/MMAC1 Gene in Human Uterine Cancers. Molecular Carcinogenesis, 2, 110-116.
http://dx.doi.org/10.1002/(SICI)1098-2744(200002)27:2<110::AID-MC6>3.0.CO;2-E - 18. Guo, R.X., Wei, L.H., Zhao, D., et al. (2006) [Effects of ICI182780 (Faslodex) on Proliferation and Apoptosis Induced by 17β-Estradiol in Endometrial Carcinoma Cells]. Beijing Da Xue Xue Bao, 38, 470-474. (In Chinese)
- 19. Amant, F., Moerman, P., Neven, P., et al. (2005) Endometrial Cancer. The Lancet, 366, 491-505.
http://dx.doi.org/10.1016/S0140-6736(05)67063-8 - 20. Cantley, L.C. (2002) The Phosphoinositide 3-Kinase Pathway. Science, 296, 1655-1657.
http://dx.doi.org/10.1126/science.296.5573.1655 - 21. Cantley, L.C. and Neel, B.G. (1999) New Insight into Tumor Suppression: PTEN Suppresses Tumor Formation by Restraining the Phosphoinositide 3-Kinase/AKT Pathway. Proceedings of the National Academy of Sciences of the United States of America, 96, 4240-4245.
http://dx.doi.org/10.1073/pnas.96.8.4240 - 22. Steelman, L.S., Pohnert, S.C., Shelton, J.G., et al. (2004) JAK/STAT, Raf/MEK/ ERK, PI3K/Akt and BCR-ABL in Cell Cycle Progression and Leukemogenesis. Leukemia, 18, 189-218.
http://dx.doi.org/10.1038/sj.leu.2403241 - 23. Lee, E.R., Kim, J.Y., Kang, Y.J., et al. (2006) Interplay between PI3K/Akt and MAPK Signaling Pathways in DNA-Damaging Drug-Induced Apoptosis. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research, 1763, 958-968.
http://dx.doi.org/10.1016/j.bbamcr.2006.06.006
NOTES
*Corresponding author.